Thus, our data are consistent with a model whereby ErbB2-dependent ERK activation downregulates IRF6, IRF6 downregulation causes reduction in the cellular BLNK levels, whereas BLNK loss in turn inactivates p38MAPK and thus blocks breast cancer cell anoikis (Fig. 6H). Here, ERBB2 is linked to breast cancer.